Special issue on in vitro MN trial

James M Parry; Micheline Kirsch-Volders

doi:10.1016/j.mrgentox.2010.07.004

Special issue on in vitro MN trial

Mutat Res. 2010 Oct 29;702(2):132-4. doi: 10.1016/j.mrgentox.2010.07.004. Epub 2010 Jul 21.

Authors

James M Parry¹, Micheline Kirsch-Volders

Affiliation

¹ School of Medicine, University of Wales-Swansea, Swansea, United Kingdom.

PMID: 20654729
DOI: 10.1016/j.mrgentox.2010.07.004

Abstract

In this commentary we are addressing some additional thoughts on the in vitro MN test: its predictivity for in vivo MN assays, its sensitivity, and how the choice of the cell line and the protocol (with or without cytochalasin-B) can influence these aspects. These considerations might help to make the in vitro MN test a reliable, toxicologically relevant and sensitive in vitro genotoxicity test covering both clastogenic and aneugenic events, and predictive for in vivo genotoxicity, in humans as well.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aneugens / toxicity*
Cell Line
Cytochalasin B / pharmacology
Genetic Testing
Guidelines as Topic
Humans
Micronucleus Tests / methods
Micronucleus Tests / standards*
Sensitivity and Specificity

Substances

Aneugens
Cytochalasin B